Securities Code: 300497
Securities Abbreviation: Fuxiang Shares
Announcement No.: 2026-082
Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Resolution Announcement of the Third Extraordinary General Meeting of Shareholders in 2026
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
Special Notes:
-
No proposals were rejected at this shareholder meeting.
-
This shareholder meeting does not involve changes to previous shareholder meeting resolutions.
I. Meeting Convening and Attendance
- Meeting Convening
Jiangxi Fuxiang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") convened its third extraordinary general meeting of shareholders in 2026 on August 17, 2026 (Monday) at 2:30 PM in the company conference room at No. 2, Yuli Industrial Zone, Changjiang District, Jingdezhen City, Jiangxi Province. The meeting was presided over by Chairman Bao Jianhua.
The meeting was convened by the Board of Directors and was held through a combination of on-site registered voting and online voting. The online voting period through the Shenzhen Stock Exchange system was: August 17, 2026, 9:15 AM - 9:25 AM, 9:30 AM - 11:30 AM, and 1:00 PM - 3:00 PM; the voting period through the Shenzhen Stock Exchange's internet voting system was any time between 9:15 AM and 3:00 PM on August 17, 2026.
The convening and voting procedures of the meeting comply with relevant laws, administrative regulations, departmental rules, normative documents, and the company's articles of association.
- Attendance
Overall shareholder attendance:
A total of 290 shareholders attended the meeting through on-site and online voting, representing 118,379,128 shares, or 21.9770% of the total voting shares. Among them, 5 shareholders attended through on-site voting, representing 109,026,300 shares, or 20.2407% of the total voting shares. 285 shareholders attended through online voting, representing 9,352,828 shares, or 1.7363% of the total voting shares.
Overall attendance of small and medium shareholders:
A total of 285 small and medium shareholders attended through on-site and online voting, representing 9,352,828 shares, or 1.7363% of the total voting shares. Among them, 0 small and medium shareholders attended through on-site voting, representing 0 shares, or 0.0000% of the total voting shares. 285 small and medium shareholders attended through online voting, representing 9,352,828 shares, or 1.7363% of the total voting shares.
- Company directors and the lawyer appointed by the company attended this shareholder meeting. The company's board secretary and other senior management personnel were present at the meeting.
II. Proposal Review and Voting Results
The meeting reviewed the following proposals through a combination of on-site registered voting and online voting, and resolutions were formed:
- Resolution on the Proposal Regarding the Company Meeting the Conditions for Issuing Shares to Specific Targets
Voting results: 117,405,047 votes in favor, accounting for 99.1772% of the total valid voting shares of shareholders attending the meeting; 499,381 votes against, accounting for 0.4218% of the total valid voting shares; 474,700 abstentions, accounting for 0.4010% of the total valid voting shares.
Among them, the total voting results for small and medium shareholders: 8,378,747 votes in favor, accounting for 89.5852% of the total valid voting shares of small and medium shareholders attending the meeting; 499,381 votes against, accounting for 5.3394% of the total valid voting shares; 474,700 abstentions, accounting for 5.0755% of the total valid voting shares.
Resolution result: This proposal is a special resolution, which was passed by more than two-thirds of the voting rights held by the shareholders present at the meeting.
- Review and Approval of the Proposal Regarding the Company's Plan for Issuing Shares to Specific Targets in 2026
The specific plan for the Company's issuance of shares to specific targets in 2026 (hereinafter referred to as "this issuance") is as follows: